The Sarcoma Foundation of America (SFA) is national cancer research non-profit. Founded in 2000, the SFA advocates for increased research to find new and better therapies with which to treat patients with sarcoma, a rare cancer of soft tissue and bone. Sarcoma is a rare cancer in adults (1% of all adult cancers), but rather prevalent in children (about 20% of all childhood cancers). There are nearly 15,000 new cases and 6,000 deaths each year in the United States. At any one time, more than 50,000 patients and their families are struggling with sarcoma.
In order to pave the way for new and better therapies, with a goal of ultimately finding the cure, the SFA has invested heavily in innovative research. Since its inception, the SFA has invested more than $7 million in research efforts, including awarding more 115 SFA Sarcoma Research Grants to scientists at research institutions across the United States. In 2014, the SFA help fund an investigator-initiated clinical trial evaluating the efficacy of Keytruda, a novel immunotherapy targeting the PD-1 receptor, for the first time in sarcoma patients.
The SFA interacts with public, private for-profit, and private non-profit entities to educate and raise awareness about the treatment needs of sarcoma patients and to advocate for increased research funding. The organization has also developed an education conference series, bringing patients and caregivers together with leading sarcoma researchers and physicians. These conferences are an exceptional opportunity for patients to learn about developments in research, clinical trials, and treatments, including immunotherapies.
For more information about the Sarcoma Foundation of America, please visit www.curesarcoma.org or connect with the SFA on social media at https://www.facebook.com/CureSarcoma/ and https://twitter.com/CureSarcoma.